Kymera Therapeutics, Inc. | Business Contracts

Registration Rights Agreement, dated August 18, 2022, by and among Kymera Therapeutics, Inc. and the persons party thereto (Filed With SEC on August 19, 2022)

Second Amendment to Master Collaboration Agreement between the Registrant and Vertex Pharmaceuticals Incorporated, dated as of October 21, 2021 (Filed With SEC on February 24, 2022)

Amended and Restated Non-Employee Director Compensation Policy dated January 17, 2022 (Filed With SEC on February 24, 2022)

Description of Securities (Filed With SEC on March 11, 2021)

Lease Agreement between the Registrant and ARE-TECH SQUARE, LLC, dated as of February 28, 2018 (Filed With SEC on July 31, 2020)

Securities Purchase Agreement, dated August 18, 2022, by and among Kymera Therapeutics, Inc. and the persons party thereto (Filed With SEC on August 19, 2022)

Form of Pre-Funded Warrant (Filed With SEC on August 19, 2022)

Form of Underwriting Agreement (Filed With SEC on June 28, 2021)

First Amendment to Master Collaboration Agreement between the Registrant and Vertex Pharmaceuticals Incorporated, dated as of August 27, 2020 (Filed With SEC on November 5, 2020)

First Amendment to Collaboration Agreement between the Registrant and GlaxoSmithKline Intellectual Property Development Limited, dated as of August 27, 2020 (Filed With SEC on November 5, 2020)

Amended and Restated 2020 Employee Stock Purchase Plan (Filed With SEC on November 5, 2020)

Form of Common Stock Purchase Agreement between the Registrant and Vertex Pharmaceuticals Incorporated (Filed With SEC on August 17, 2020)

Form of Indemnification Agreement between the Registrant and each of its directors and executive officers (Filed With SEC on August 17, 2020)

2020 Employee Stock Purchase Plan (Filed With SEC on August 17, 2020)

2020 Stock Option and Incentive Plan, and form of award agreements thereunder (Filed With SEC on August 17, 2020)

Specimen Common Stock Certificate (Filed With SEC on August 17, 2020)

Form of Underwriting Agreement (Filed With SEC on August 17, 2020)

Form of Amended and Restated Employment Agreement (Filed With SEC on August 13, 2020)

Senior Executive Cash Incentive Bonus Plan (Filed With SEC on August 13, 2020)

Non-Employee Director Compensation Policy (Filed With SEC on August 13, 2020)

Collaboration Agreement between the Registrant and GlaxoSmithKline Intellectual Property Development Limited, dated as of October 3, 2017 (Filed With SEC on August 5, 2020)

2018 Stock Option and Grant Plan, and form of award agreements thereunder (Filed With SEC on July 31, 2020)

Second Amended and Restated Investors Rights Agreement among the Registrant and certain of its stockholders, effective as of March 11, 2020 (Filed With SEC on July 31, 2020)

Kymera Therapeutics, Inc. (23)